Cognitive Screening in Lung Cancer Patients

European Institute of Oncology

Status: Enrolling

Conditions: NSCLC (Non-small Cell Lung Cancer); Lung Disease; SCLC

Study type: Observational

Funder types: Other

Identifiers

NCT06727370

IEO 2027

Details and patient eligibility

About

This study aims to investigate the occurrence of cancer and adjuvant therapy-related cognitive impairment in patients with both NSCLC and SCLC. The primary endpoint measure will be the presence of cognitive impairment during the first year after enrollment through the administration of a comprehensive neuropsychological assessment.

Enrollment: 200 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Small-cell and non-small-cell lung cancer (stage I, II, III, IV)
• Age ≥ 18 years
• Patients able to speak and read the local language(s) fluently
• Acceptance and signature of informed consent

Exclusion criteria

• Age ≥ 70
• Presence of brain metastases
• Patients with concomitant neurological or psychiatric disorders.
• Patients undergoing brain radiotherapy
• Previous diagnosis of lung cancer

Trial design

200 participants in 1 patient group

patients diagnosed with lung cancer

Description:

patients diagnosed with lung cancer (both SCLC and NSCLC)